COURSE DESCRIPTION

Development of inhibitory antibodies in hemophilia A and B remains a major complication in the management of patients, jeopardizing the outcome of treatment. The ultimate goal should be tolerization towards the deficient factor by immune tolerance induction (ITI) therapy. This procedure is however often complex and associated with several issues. The aim of the course is to highlight latest knowledge, current challenges of ITI treatment and different therapeutic options – in an era of new potential approaches to assure the best care of patients who have developed inhibitors.

**Outcome for participants:** Increased knowledge and understanding about:

- Immunology in inhibitor development and ITI
- Therapeutic ITI options to eradicate an inhibitor and induce tolerance
- New and emerging treatment options for patients with inhibitors
- Laboratory methods and pitfalls of measuring inhibitors during ITI
- How to manage and prevent bleedings before and during ITI
- Practical issues in association with ITI and how to manage co-morbidities
- Specific issues to consider in the management of inhibitors in patients with non-severe hemophilia A and severe hemophilia B

**Course content:** See attached programme

**Methodology:** The course is based on outlined lectures and interactive authentic case studies in accordance with case methodology. The course includes an examination addressing main messages. Participants will receive access to the course content so that the message can be passed on to their own department.

**Target group:** Physicians treating hemophilia. Participants should have previous ITI experience. Good English skills are required.

**Selection criteria:** International mix of participants. The application should be approved and the background as mentioned above consolidated. Number of seats is limited.

**Accreditation:** LIPUS (Institute for the Professional Development of Physicians in Sweden) will review the course (www.lipus.se).

CME (Continuing Medical Education) application pending (EACCME)

The course is sponsored by Octapharma and provided by Lund University and the Malmö Centre for Thrombosis and Haemostasis at Skåne University Hospital in collaboration with international hemophilia experts.